New drug cocktail aims to stop liver cancer recurrence
NCT ID NCT05367687
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether adding rivoceranib to camrelizumab after surgery or ablation helps prevent liver cancer from coming back in high-risk patients. 251 participants were randomly assigned to receive either the combination or camrelizumab alone. The main goal was to see how long patients stayed cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab and rivoceranib (apatinib)
- What this could lead to
- If successful, this combination could offer a new way to delay or prevent liver cancer from coming back after surgery or ablation.
- What could go wrong
- This is a phase 2 trial with a moderate number of participants, so results are not definitive. The combination may cause more side effects than camrelizumab alone, and it is not yet known if it improves long-term survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AT HIGH RISK OF RECURRENCE AFTER CURATIVE RESECTION OR ABLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer vaccine prime the body to better fight liver tumors?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- Can a tumor-zapping procedure also wake up the immune system?
- A machine that keeps donor livers alive outside the body — could it transform transplantation?